

Appl. No. 10/798,198
Amdt. dated March 6, 2006
Reply to Office Action of February 6, 2006


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

The claimed invention is:

Claim 1 (Original): A compound of formula (I):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted $(\text{C}_1\text{-C}_8)$ alkyl, $(\text{C}_3\text{-C}_7)$ cycloalkyl, $(\text{C}_3\text{-C}_9)$ aryl, $(\text{C}_3\text{-C}_9)$ heteroaryl, amide, amino, $(\text{C}_1\text{-C}_8)$ alcohol, $(\text{C}_3\text{-C}_9)$ heterocycloalkyl, $(\text{C}_1\text{-C}_8)$ alkyl $(\text{C}_3\text{-C}_9)$ aryl, $(\text{C}_1\text{-C}_8)$ alkylamine, $(\text{C}_1\text{-C}_8)$ alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl;

R^3 is independently selected from the group consisting of H, $(\text{C}_1\text{-C}_8)$ alkyl, halo, $(\text{C}_1\text{-C}_8)$ alkoxy, sulfonyl, cyano, and keto;

n is an integer from 0-5;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.


Claim 2 (Original): A compound of claim 1, wherein R^3 is H, bromo, chloro, cyano, methoxy, $(\text{C}_1\text{-C}_8)$ alkyl- SO_2 -, or $(\text{C}_1\text{-C}_8)$ alkyl $\text{C}(=\text{O})$ -.

Claim 3 (Original): A compound of claim 1, wherein n is 0-4.

Appl. No. 10/798,198
Amdt. dated March 6, 2006
Reply to Office Action of February 6, 2006

Claim 4 (Original): A compound of claim 3, wherein n is 0-1.

Claim 5 (Withdrawn): A compound of formula (II):



or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R^1 is H;


R^2 is a substituted or unsubstituted ($\text{C}_1\text{-C}_8$)alcohol, ($\text{C}_3\text{-C}_9$)cycloalkyl, ($\text{C}_3\text{-C}_9$)heterocycloalkyl, ($\text{C}_3\text{-C}_9$)heteroaryl, ($\text{C}_1\text{-C}_8$)alkylamine, ($\text{C}_1\text{-C}_8$)alkyl($\text{C}_3\text{-C}_9$)aryl, or ($\text{C}_1\text{-C}_8$)alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycloalkyl or heteroaryl group;

Het is a substituted or unsubstituted heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

Claim 6 (Withdrawn): A compound of claim 5, wherein Het is a substituted or unsubstituted ($\text{C}_5\text{-C}_{10}$)heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

Claim 7 (Withdrawn): A compound of claim 6, wherein Het is a substituted or unsubstituted furanyl, thienyl, pyridyl, or benzofuranyl group.

Claim 8 (Withdrawn): A compound of formula (III):



Appl. No. 10/798,198
Amdt. dated March 6, 2006
Reply to Office Action of February 6, 2006

or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof where:

R¹ is H;

R² is a substituted or unsubstituted (C₁-C₈)alcohol;

Ar is a substituted or unsubstituted (C₃-C₉)aryl group;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

Claim 9 (Withdrawn): A compound of claim 8, wherein R² is a substituted or unsubstituted (C₁-C₅)alcohol.

Claim 10 (Withdrawn): A compound of claim 9, wherein R² is a substituted or unsubstituted (C₃-C₅)alcohol.

Claim 11 (Withdrawn): A compound of claim 8, wherein Ar is a substituted or unsubstituted naphthyl group.

Claim 12 (Withdrawn): A pharmaceutical composition comprising a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier.

Claim 13 (Withdrawn): A method of preventing or treating a TGF-related disease state in a mammal (animal or human) comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1-11 to the animal or human suffering from the TGF-related disease state.

Claim 14 (Withdrawn): A method of claim 13, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

Claim 15 (New): A compound of claim 1 wherein

R² is a substituted or unsubstituted (C₁-C₈)alkyl(C₃-C₉)aryl;

Appl. No. 10/798,198
Amdt. dated March 6, 2006
Reply to Office Action of February 6, 2006

R^3 is independently selected from the group consisting of H, (C₁-C₈)alkyl, halo, (C₁-C₈)alkoxy, sulfonyl, cyano, and keto; and
n is 0-4.

Claim 16 (New): A compound of claim 15, where R^3 is independently selected from the group consisting of H, or bromo, chloro, and methoxy.

Claim 17 (New): A compound of claim 16 wherein n=0 and R^2 is an unsubstituted (C₁-C₈)alkyl(C₃-C₉)aryl.

Claim 18 (New): A compound of claim 17 wherein said (C₁-C₈)alkyl(C₃-C₉)aryl is CH₂ phenyl.

Claim 19 (New): The compound 3-amino-6-phenyl-pyrazine-2-carboxylic acid benzylamide.